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Abstract
Background: Prevalence of insomnia symptoms in the general population is high. Insomnia is linked with high health
care use and within primary care there are a number of treatment options available. The objective of this study was to
determine the association of persistence and remission of insomnia with primary health care using a longitudinal study.
Methods: A postal survey of registered adult (over 18 years) populations of five UK general practices, repeated
after 1 year, linked to primary care records. Baseline survey responders were assessed for persistence of insomnia
symptoms at 12 months. The association of primary care consultation or prescription for any mood disorder
(defined as anxiety, depression, stress, neurosis, or insomnia) in the 12 months between baseline and follow-up
surveys with persistence of insomnia was determined.
Results: 474 participants reporting insomnia symptoms at baseline were followed up at 12 months. 131(28%)
consulted for mood problem(s) or received a relevant prescription. Of these 100 (76%) still had insomnia symptoms
at one year, compared with 227 (66%) of those with no contact with primary care for this condition (OR 1.37; 95%
CI 0.83, 2.27). Prescription of hypnotics showed some evidence of association with persistence of insomnia at
follow-up (OR 3.18; 95% CI 0.93, 10.92).
Conclusion: Insomniacs continue to have problems regardless of whether or not they have consulted their
primary care clinician or received a prescription for medication over the year. Hypnotics may be associated with
persistence of insomnia. Further research is needed to determine more effective methods of identifying and
managing insomnia in primary care. There may however be a group who have unmet need such as depression
who would benefit from seeking primary health care.
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Background
The reported prevalence of insomnia in the general
population is high, varying between 6% and 37%
depending on the criteria used. Insomnia may be
defined as simply self-reported “difficulty sleeping” on
one or more nights in the previous month or more
stringently using, for example, the DSM-IV criteria of
primary insomnia which excludes insomnia associated
with psychiatric or physical illness [1-8]. Insomnia is a
common accompaniment to anxiety and depression,
with around two-thirds of those with insomnia reporting
anxiety or depression and it may be an early symptom
of depression [6-10]. This link with psychological dis-
tress may be one reason for the high health care use in
people with insomnia, an increased number of accidents
at work, presence of comorbidity and greater use of
medication than good sleepers [7,11,12].
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the natural history of insomnia is not fully explored.
There are several studies which have examined the out-
come in primary care for people presenting with insom-
nia, and in particular how this relates to management.
Foley et al. observed a persistence of insomnia symp-
toms of 52% in elderly patients in the community over a
three year period, persistence being significantly and
independently associated with physical disability, depres-
sion and sedative use [13]. Janson et al. in a 10 year pro-
spective study of adult men in the community reported
associations of insomnia with medical and psychiatric
disorders, remission being related to weight loss and
smoking cessation; however medication use was not
reported [4]. Simon et al. in a community study with a
3 month telephone follow-up likewise found a positive
association between insomnia and healthcare use,
although this appears to have been closely linked to
depression [14].
There are a plethora of treatments available to primary
care clinicians for the management of patients with
insomnia, both pharmacological and non-pharmacologi-
cal. This may bear testament to the fact that no treat-
ment is both effective and without side effects, although
cognitive behavioural therapy and the melatonin agonist
ramelteon appear promising [7,8,15-18]. Improvements
in insomnia following CBT interventions delivered over
the internet persisted at 6 month follow-up [18].
We previously reported results from a baseline health
survey, linked to medical record review, of health care
u s ef o ri n s o m n i aa n dm o o dp r o b l e m s[ 9 ] .O ft h o s e
reporting insomnia at baseline, 30% had either a consul-
tation for a mood disorder or a prescription during the
following 12 months, with 21% receiving antidepressants
and 8% receiving hypnotics.
This study aimed to use a 12 month follow-up survey
of this population to determine the relationship of pre-
scribed medication and consultations for insomnia or
anxiety and depression with persistence of self-reported
insomnia symptoms.
Methods
This was a prospective cohort study linking baseline and
12 month survey to medical record review [1]. Ethical
approval for the study was granted by the North Staf-
fordshire Local Research Ethics Committee. Random
selection of patients aged 18 plus was made by compu-
ter from the registered populations of five general prac-
tices in the UK. More than 95% of the UK population
are registered with a general practice, which provides a
convenient sampling frame of the general population in
a locality. One thousand patients from each practice (a
total of 5000 patients) were selected. 115 people were
excluded as they were currently in hospital, recently
died, left the practice, or were excluded by their GP as
suffering from severe mental illness. 4885 questionnaires
were therefore sent out in April 2000 with a follow-up
questionnaire 1 year later. This study was carried out to
investigate headaches and general health, but included
questions about sleep, which we have used as a basis for
this new investigation.
Jenkins et al. have developed four questions related to
insomnia and these were included in both baseline and
one year follow-up questionnaires [19]. These were:-
“Over the last month did you i) Have trouble falling
asleep, ii) Wake up several times a night, iii) Have trou-
ble staying asleep, iv) Wake up after your usual amount
of sleep feeling tired and worn out’?”. Possible responses
were ‘N o ta ta l l ,O ns o m en i g h t s ,O nm o s tn i g h t s ’.O u r
main definition of insomnia was based on answering
one or more of these questions"on most nights”.
The Hospital Anxiety and Depression Scale (HADS) was
used to assess anxiety and depression [20,21]. Respondents
who scored 8 or over on either of the two domains were
classified as having self-reported anxiety or depression.
Pain is closely associated with insomnia, and is likely
to be a confounder between poor sleep and the use of
primary health care [22]. The participants were asked to
shade in on a diagram of a blank body manikin any
aches or pains lasting for 1 day or more in the previous
month. Number of pain sites was categorised into 0, 1-3
and 4-7 sites.
Consent to examine their medical records was sought
from people in the survey population. For the 1 year
between the baseline and follow-up questionnaires, rele-
vant consultations and prescription data for mood disor-
ders were extracted. These were defined as either
insomnia, or anxiety or depression recorded as the pre-
senting problem, or prescriptions in the groups listed
below. Prescription medication data was extracted from
the records by British National Formulary categories
(BNF) 4.1 and 4.3. All antidepressants (BNF 4.3), includ-
ing tricyclics and serotonin reuptake inhibitors may be
used in the treatment of insomnia, whereas hypnotics
(BNF 4.1.1) and anxiolytics (BNF 4.1.2) have different
clinical applications. Anxiolytics such as diazepam,
chlordiazepoxide and lorazepam were little used in the
treatment of insomnia in this group. Categories 4.1.3
(barbiturates) and 4.3.2 (monoamine oxidase inhibitors)
had not been prescribed to these patients. The hypnotics
(BNF 4.1.1), include the benzodiazepine receptor ago-
nists zopiclone, zolpidem, zaleplon, shorter acting ben-
zodiazepines, temazepam and lometazepam and the
longer acting nitrazepam and flurazepam.
Analysis
Respondents to the baseline questionnaire who
answered positively to any of the insomnia questions on
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care over the next year and analysed as regards to their
responses to the insomnia questions in the follow-up
questionnaire.
The association of any self-reported insomnia symp-
tom at follow-up with relevant health care use for mood
disorder was determined after adjustment for self
reported baseline anxiety and depression, age, gender,
number of insomnia symptoms and number of pain
areas. The analysis was repeated for the four individual
insomnia symptoms. Analysis was performed using
logistic regression with results presented as odds ratios
and 95% confidence intervals. SPSS 15.0 for Windows
was used.
Results
A flow diagram of participants is given in Figure 1. Of
the 4885 questionnaires sent out, 2662 were returned at
baseline. Following adjustment for deaths and change of
address the response rate was 56%. Response was higher
in females (61% compared to 51% in males) and in older
age groups (65% in those aged 65+ compared to 43% in
those aged 18-35). 2363 answered all the sleep questions
and of these 2192 consented to examination of their
medical records. Of the 2192 responders, 735 reported
an insomnia symptom at baseline. Of these, 474 (64%)
consented to follow-up at 12 months, returned a follow-
up questionnaire and completed the follow-up insomnia
questions.
Compared to those reporting insomnia at baseline
who did not consent to record review or did not com-
plete the questionnaire at follow-up, the 474 participants
who were followed up were no different in terms of
gender (female: 63% v. 60%), age (mean 52 v. 51), levels
of anxiety or depression at baseline (68% v. 70%), or
reporting multiple pains at baseline (pain in more than
4 sites: 52% v. 47%). When further compared with those
who reported insomnia at baseline and consented to
record review but did not complete the follow-up ques-
tionnaire, in the 12 months after baseline the 474 parti-
cipants had a similar prevalence of consultation for a
mood disorder (18% v. 20%) and hypnotic prescription
(8% v. 8%), but slightly lower level in terms of anti-
depressant prescription (19% v. 23%).
Persistence of any insomnia symptom
327 (69%) of the 474 participants continued to suffer
from an insomnia symptom at follow-up. Of the 343
who had no consultation or prescription for a mood dis-
order during the one year follow-up period, 227 (66%)
still had insomnia at 12 months. Of the remaining 131
who had consulted or been given a prescription for a
mood disorder, 100 (76%) still had insomnia at 12
months. In the unadjusted analysis, any consultation or
prescription for mood disorder was associated with per-
sistence of insomnia problems (OR 1.65; 95% CI 1.04,
2.61) although this association was reduced after adjust-
ment for age, gender, pain, anxiety or depression, and
number of symptoms (OR 1.37; 95% CI 0.83, 2.27).
Baseline anxiety and depression had a similar level of
association as consultation or prescription had with per-
sistence of insomnia problems (OR 1.39; 95% CI 0.87,
2.22).
Prescriptions for hypnoticsw e r es t r o n g l ya s s o c i a t e d
with persistence of insomnia in the unadjusted analysis
with 33 (92%) of those receiving a hypnotic still having
Figure 1 Flow diagram of participants.
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This association was still strong although not statistically
significant after adjustment (OR 3.18; 95% CI 0.93,
10.92). There was no association of persistent insomnia
with antidepressants. (Table 1)
Persistence of individual symptoms
In those reporting “trouble falling asleep” at baseline,
having a consultation or prescription for a mood disor-
der was suggestive of higher rates of persistence of this
symptom at 12 months although the association was not
statistically significant (adjusted OR 1.98; 95% CI 0.98,
4.02). A similar finding occurred for the symptom “trou-
ble staying asleep” (adjusted OR 1.78; 95% CI 0.93, 3.43).
There was little apparent relationship of persistence with
health care use for either of the other two symptoms:
waking up several times or waking up tired and worn
out. (Table 2)
Discussion
This study linked baseline and 12 month postal surveys
in a general population sample with primary care
medical records. Those receiving primary care for mood
disorders did not have better outcomes in terms of
remission of their insomnia symptoms. In those report-
ing insomnia at baseline, three-quarters of those receiv-
ing health care management still had symptoms at
follow-up.
This study found persistent insomnia symptoms were
higher in people prescribed hypnotic drugs, but there
was no association with antidepressant use. Foley et al.
also found a close relationship between sedative medica-
tion and persistence of insomnia symptoms over 3 years
in an elderly population in the community [13]. In
elderly women (aged 70-75 yrs) Byles et al. found that
over 75% of those taking hypnotics at baseline contin-
ued to take these drugs at follow-up 4 years later [23]
Belleville et al. found that withdrawal of hypnotics over
an 8 week period in a group of chronic users of this
medication resulted in over 68% of participants in the
study being drug free, and 51% still being drug free at 6
months. This was independent of whether or not the
tapering dose of hypnotics was combined with self-help
CBT in the form of a graded program of literature [24].
Table 1 Reporting of insomnia at 12 months by health care use in those who self-reported insomnia at baseline
Reported Insomnia 12 months
Total Yes No OR
a OR
b
n (%) n
Hypnotics
No 438 294 (67) 144 1.00 1.00
Yes 36 33 (92) 3 5.38 (1.63, 17.86) 3.18 (0.93, 10.92)
Any antidepressant
No 383 260 (68) 123 1.00 1.00
Yes 91 67 (74) 24 1.32 (0.79, 2.21) 1.12 (0.64, 1.96)
Any mood
consultation No 343 227 (66) 116 1.00 1.00
or prescription Yes 131 100 (76) 31 1.65 (1.04, 2.61) 1.37 (0.83, 2.27)
a unadjusted
b adjusted for age, gender, number of insomnia symptoms, pain, anxiety or depression at baseline
Table 2 Reporting of individual insomnia symptoms at 12 months by health care use in those who self-reported
insomnia at baseline
Reported Insomnia 12 months
Total Yes No OR
a OR
b
n (%) n
Trouble falling asleep Any mood consultation No
or prescription Yes
97
66
51 (53)
46 (70)
46
20
1.00
2.08 (1.07, 4.01)
1.00
1.98 (0.98, 4.02)
Wake up several times Any mood consultation No
or prescription Yes
269
110
177 (66)
70 (64)
92
40
1.00
0.91 (0.57, 1.44)
1.00
0.78 (0.46, 1.32)
Trouble staying asleep Any mood consultation No
or prescription Yes
167
74
92 (55)
53 (72)
75
21
1.00
2.06 (1.14, 3.71)
1.00
1.78 (0.93, 3.43)
Wake up tired and worn out Any mood consultation No
or prescription Yes
177
89
93 (53)
55 (62)
84
34
1.00
1.46 (0.87, 2.46)
1.00
1.36 (0.77, 2.42)
a unadjusted
b adjusted for age, gender, pain, number of insomnia symptoms, anxiety and depression at baseline
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died over six years found that persistence of insomnia
was related both to psychiatric and physical symptoms
and a past history of insomnia [25].
Regardless of primary care use, two-thirds of this sam-
ple still had insomnia symptoms at follow-up. This sug-
g e s t st h a ti nm o s tp e o p l ew i t hi n s o m n i as y m p t o m si n
the community these symptoms are chronic. The major-
ity did not consult or have a prescription for this pro-
blem, some possibly choosing to self medicate. Our
previous work showed a clear link between insomnia
and depression, this non-consulting group may have
unmet need such as depression [9]. Alternatively they
may see that primary care is routinely only offering drug
treatments with possible side effects. Horne, for exam-
ple, suggests that some people perceive medication
negatively as unnatural or dangerous and prefer to self-
medicate [26]. Included in this group will also be some
with milder symptoms.
Remission is seen in one-third of people with insom-
n i aa tb a s e l i n ew h od on o th a v eac o n s u l t a t i o no rp r e -
scription. This no doubt represents the temporary
nature of the insomnia stimulus in some but is broadly
in agreement with Foley et al. who found a 48% remis-
sion of insomnia after 3 years in the community on no
sedative medication, decreasing to 33-37% at follow-up
when sedative medication was taken [13]. Janson et al.
found a remission rate of 65% in men aged 30-69 yrs
after a 10 year follow-up, associated with smoking cessa-
tion and weight loss, although medication use was not
recorded [4]. Even in the more severe insomniacs found
in a sleep medicine clinic in the US, Rosenthal et al.
(2008), reported the remission of insomnia over 3 to 5
years to be 26% [27]. In Morin et al’s general population
study of those complaining of poor sleep, 31% had what
was described as insomnia syndrome, which included
those who were dissatisfied with sleep and having
insomnia for 3 nights a week for at least a month or
those who took hypnotics. At 3 year follow-up 30% of
the insomnia syndrome group had persistence of their
symptoms and only 8% of this group had spontaneous
remission [28].
Hypnotic use appears associated with an increased
likelihood of persistence. There are several interpreta-
tions of this result. Hypnotic medication may be ineffec-
tive in the long-term in primary care and potentially
exacerbates the problem, this exacerbation may be due
to a specific problem of tolerance and addiction related
to both persistence and medication use [29]. The group
of people with insomnia who receive prescriptions for
hypnotics may in some way be “different” to people who
do not take hypnotics or do not consult primary care, in
ways which might explain poor outcome despite
medication.
Whatever the explanation, however, primary care is
having little impact on community levels of chronic
insomnia with its current range or style of medications.
However cognitive behavioural therapy (CBT) may be as
effective and with less side effects than medication [30].
Internet-based CBT may be attractive in that it is a low-
cost alternative to face to face CBT [18]. The GP may
w i s hf i r s tt og i v es l e e ph y g i e n ea d v i c eo ro r g a n i s eC B T
if this is available when faced with a patient with com-
plaints of insomnia.
A strength of this study is its longitudinal design with
surveys at baseline and 12 months linked by consulta-
tion and prescription data. Associations were adjusted
for age, gender, and number of pain areas, all of which
have been shown to be related to both insomnia and
health care use [12]. Existence of other chronic illnesses,
for example cardiac, respiratory disease or diabetes,
were not measured and may be associated with insom-
nia and hence may have an influence on the results
[31]. We did not measure over the counter medication
which may have been used to self-treat insomnia.
Response at baseline was 56% and there were some age
and gender differences in response. As with all cohort
studies, there was further attrition at follow-up. How-
ever, there were few differences between those complet-
ing follow-up questionnaires and those who did not in
demographics, self-reported anxiety or depression, self-
reported pain, or health care use for a mood disorder.
Whilst any selective non-response may affect the overall
estimates of rates of consultation and prescription, it is
unlikely to affect the associations found.
Consultation data for mood problems and prescrip-
tions for hypnotics and antidepressants were examined
for 1 year between the questionnaires at baseline and
follow-up, so it was not possible to ascertain whether
health care use was new or ongoing. The study was set
in North Staffordshire, UK, an area more deprived than
the UK average. However data were collected from five
general practices which should reduce the likelihood
that health care use was influenced by unusual practice
characteristics.
Conclusions
Those with insomnia symptoms continue to have pro-
blems regardless of whether they receive primary care
management or not. Hypnotic use appears to be related
to persistence of insomnia. Further research is needed
to determine the most effective methods of identifying
and managing insomnia in primary care. There is also a
large group of people with persistent insomnia who do
not seek primary health care. The reasons for this need
t ob ee s t a b l i s h e da st h e ym a yh a v eu n m e tn e e ds u c ha s
depression and may benefit from seeking primary health
care.
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